Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Hanka de Voogd

Department of Clinical Development, Mylan Laboratories Limited, USA

Biography

Dr. Hanka de Voogd currently works at the Clinical Development, Mylan Laboratories Limited. Hanka does research in Internal Medicine (General Medicine) and Infections/vaccines. Their most recent publication is 'Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: A retrospective cohort study'.
Publications

Evaluation of the Effectiveness of Risk Minimisation Measures Targeting Physicians on Prescribing Practices of Thiocolchicoside Containing Medicinal Products for Systemic Use

Introduction: In 2014, Risk Minimisation Measures (RMMs) concerning thiocolchicoside for systemic use were implemented in all European countries marketing the product. A Direct Healthcare Professional Communication (DHPC) and Educational Materials (EMs), were distributed to health care professionals to increase awareness related to genotoxicity ris... Read More»

Laurence Sophie Jouaville, Carole Ehrhardt, Marie-Laure Kürzinger, Hanka de Voogd and Massoud Toussi

: Epidemiology (Sunnyvale) 2019, 9: 372

10.4172/2161-1165.1000372

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Top